The epidemiology and chemotherapeutic approaches to the control of urinary schistosomiasis in school-age children (SAC): a systematic review

Tolulope Ebenezer Atalabi and Taiwo Oluwakemi Adubi

Abstract

Background: Human schistosomiases are acute and chronic infectious diseases of poverty. Currently, epidemiological data of urinary schistosomiasis (US) in school-age children (SAC) and adults are often reported together making it difficult to ascertain the true status of the disease. Based on this premise, we set out to carry out this review.

Method: To achieve this aim, we carried out a computer-aided search of PubMed, Web of Science, Science Direct, African Journals OnLine (AJOL) and the database of World Health Organization. However, the information obtained from these sources was supplemented with additional literatures from Mendeley, Research Gate, and Google.

Results: The search yielded 183 literatures of which 93 full text research, review and online articles were deemed fit for inclusion. Our key findings showed that: (1) of all World Health Organization (WHO) Regions, Africa is the most endemic zone for US, with Kenya and Senegal recording the highest prevalence and mean intensity respectively; (2) SAC within the range of 5–16 years contribute most significantly to the transmission cycle of US globally; (3) gender is a factor to watch out for, with male often recording the highest prevalence and intensity of infection; (4) contact with open, potentially infested water sources contribute significantly to transmission; (5) parental factors (occupation and education status) predispose SAC to US; (6) economic vis a vis ecological factors play a key role in infection transmission; and (7) in the last decade, a treatment coverage of 45% was never achieved globally for SAC or non-SAC treatment category for urinary schistosomiasis.

Conclusion: In view of the WHO strategic plan to eliminate schistosomiasis by 2020 and the findings from this review, it is obvious that this goal, in the face of realities, might not be achieved. It is imperative that annual control programmes be scaled up marginally, particularly in the African region of WHO. While US-based researches should be sponsored at the grass-root level to unveil hidden endemic foci, adequate facilities for Water, Sanitation, and Hygiene (WASH) should be put in place in all schools globally.

Keywords: Prevalence, Control, Urinary, Schistosomiasis, School, Children
Background

Human schistosomiases are acute and chronic infectious diseases associated with abject poverty in 78 low and middle-income countries in the sub-tropical and tropical parts of the world where there is negligible access to potable water and adequate sanitation. The agents of etiology of these diseases are “blood-thirsty” digenetic trematodes in the genus Schistosoma [1, 2].

Freshwater gastropod snails in the genus Bulinus are suitable intermediate hosts to Schistosoma haematobium which causes urinary schistosomiasis. The transmission gap of the disease is bridged when people come into contact with unwholesome water sources [3–5] infested with the cercariae (infective larval form) which mechanically penetrates the skin of their human definitive hosts. A transmission cycle is consolidated when infected humans, due to lack of modern waste disposal facilities, indiscriminately pass urine-infested eggs in close proximity to water bodies where they hatch into larval form (called miracidia) which infect Bulinus. In humans, cercariae undergo series of larval migration before maturing into adults which migrate to the veins of the urinary tract where gravid females lay a large number of eggs which are responsible for the various signs, symptoms and morbidity associated with the disease. The classical sign of urinary schistosomiasis is haematuria, a term coined to describe the presence of blood in urine. Genital schistosomiasis causes pathological damage in both sexes, with females being more at risk of contracting Human Immuno-Deficiency Virus (HIV) [6, 7].

Nonetheless, a review of the burden of schistosomiasis has shown that over 200, 000 people die from the complications due to the disease in Sub-Saharan Africa (SSA) annually while children suffer anaemia, stunted growth [8, 9], urinary tract damage [10] and reduced mental ability to cope with academics. In advanced cases, hydronephrosis, [11] ureteral and bladder fibrosis/cancer commonly occur [6].

As a follow up to the 2001 World Health Assembly resolution WHA54.19, many endemic countries in Africa launched national control programmes largely based on preventive chemotherapeutic intervention with praziquantel (PZQ) targeting at least 75% of school-age children-SAC (5–14 years old) and adults at risk of schistosomiasis [12, 13] by 2010. This resolution aligns properly with earlier report that SAC, adolescent and young adults usually recorded the highest prevalence and intensities of schistosomiasis [14]. Meanwhile, the guideline of World Health Organization required that treatment of SAC (enrolled and not enrolled) be done: once every year for high-risk communities, once every two years for moderate-risk communities and twice during their Primary School Age in low-risk communities [13, 15].

Currently, epidemiological data on prevalence, intensity and control of US in SAC and adults are often reported together, thus making information peculiar to SAC to be insufficient in the literature. The implication of this is that it is difficult to ascertain the epidemiological status of the disease in this group to enhance the success of control programmes targeting this group. Based on this premise, the aim of this review article was to study the epidemiology and chemotherapeutic strategies to the control of US in SAC.

Methods

Search strategy

We carried out a computer-aided search of PubMed, Web of Science, Science Direct, African Journals OnLine (AJOL) and the database of World Health Organization (WHO). However, the information obtained from these sources was supplemented with additional literatures from Mendeley, Research Gate, and Google. The searches were performed independently by the authors using the key words: “urinary/urinary schistosomiasis” in combination with “prevalence”, “intensity”, “morbidity”, “control/praziquantel”, “school” and “children”.

Selection criteria

Literatures that address prevalence, intensity, morbidity, indicators or risk factors as well as the control of US, without restriction to year of publication, were included in this review article. Besides, such papers addressed school children specifically. The implication of this is that articles exclusively addressing intestinal schistosomiasis or other Neglected Tropical Diseases were not considered eligible for inclusion.

Analysis and presentation of data

The secondary data presented in this manuscript were manually extracted from the articles included in this review paper. Data imported into Microsoft Excel Spreadsheet were used to generate Bar Charts.

Results

The search

The search yielded 183 literatures. After proper scrutiny of the retrieved literatures, 93 full text research, review and online articles were deemed fit for inclusion. Consequently, this review is a product of the findings from these articles. The flow chart in Fig. 1 shows the result of our search.

Characteristics of the included articles

Of the 93 literatures included in this review, majority, 46 (49.46%), were products of researches/reviews carried out in African WHO Region, with Nigeria recording the second largest number of articles, 19 (20.43%). Switzerland in
European Region, however, accounted for the largest, 22 (23.66%), which were all technical reports/review articles (see Table 1).

The sampling years reported by the 61 research articles included in this review ranged from 1984 to 2017, with the studies executed between 2004 and 2017 being 11 times more in number than those carried out in each of 1984–1993 and 1994–2003. Sixty-Five point Fifty-Eight percent (40), 63.93% (39), and 60.66% (37) of the studies were cross-sectional in nature, carried out in school settings and rural areas respectively (see Table 1).

However, it is worthy of note that sample size determination, sampling method, and intensity of US were not reported by 49.18% (30), 54.09% (33) and 46.34% (19) of the studies included in this review (see Table 1).

Prevalence and intensity of urinary schistosomiasis
Data on the prevalence of US in different endemic settings are presented in Table 2 below. In Nigeria, the prevalent rates obtained from 14 research articles with a total sample size of 5675 ranged from 2.07%–78.43%. They showed that 2116 school children were infected, giving an overall prevalence rate of 37.29%. Coincidentally, these articles represent the six (6) geopolitical zones of Nigeria.

However, six studies from Kenya reported that of the 25,809 respondents sampled, 11,728 were infected with the infective stage of *S. haematobium*, giving a prevalence rate of 45.44%. The prevalence of US obtained from Kenya-based literatures ranged from 8.90%–94%.

Moreover, two Ethiopia-based research articles retrieved showed that of the 100,030 respondents examined, 310 tested positive for US, resulting in a prevalence rate of 0.31%.

In Cameroon, out of the 1346 school children interviewed and examined as reported by two articles, 446 were found to be suffering from the menace of US, giving a prevalence rate of 33.14%.

Furthermore, a prevalence of 67.16% was computed from a total sample size of 539 reported by two papers which showed that 362 school children were infected.

Finally, each research paper obtained from Malawi, Niger, Ghana, Burkina Faso, Yemen, Zimbabwe, Zambia and Angola reported prevalence rates (sample size) of: 14.20% (1642), 75.40% (1642), 50% (100), 8.76% (3514), 23.80% (400), 60% (551), 9.60% (2040) and 61.80% (785) respectively. Table 2 also presents the extracted data on the intensity of US. It is obvious that only 17 research articles (48.57%) reported the intensity of infection due to the disease in question. Of this figure, 12 (70.59%) presented mean intensity of infection as Arithmetic Mean while only 5 (29.41%) presented it as Geometric Mean.

By Arithmetic format of reporting mean intensity, the highest value, 154.7 eggs per 10 ml of urine sample, was reported in a survey carried out in Magba Region, Cameroon while the runner up value, 107.30 eggs per 10 ml of urine sample, was reported from Kano State, Nigeria. The overall highest mean intensity of infection was reported in Fatick Region, Senegal as a Geometric Mean Intensity of 356.1 eggs per 10 ml of urine sample. The same location recorded the second highest mean egg count of 185 eggs per 10 ml of urine sample.
As it stands, Kenya has the highest prevalence while Senegal has the highest mean intensity of infection with US among SAC.

Of the 41 research articles included in this review paper, 35 reported a total number of 144,755 participants with prevalence/intensity records. As far as *S. haematobium* egg concentration technique was concerned, 11, 18 and 4 articles recorded centrifugation, filtration, and sedimentation as means of preparing sample for viewing under the microscope. However, 2 articles from Angola and Zimbabwe did not report technique of egg concentration.

### Risk factors of urinary schistosomiasis in school children

Table 3 presents the factors that are considered pertinent to the transmission of US in school children. Findings from this review reveal that SAC within the range of 5–16 years of age were consistently and unanimously reported as the group with the highest prevalence and association with US.
By the findings in this review paper, gender played a significant role in the transmission of US, with males recording higher prevalence of infection and significant association more often over their female counterparts.

Water-related factors like swimming, playing in shallow waters, fetching water for domestic uses in open and potentially infested water bodies like lakes, rivers, ponds, streams, etc. *vis a vis* proximity of residence to sources of unwholesome water sources have all been reported by

Table 2 Urine Processing Technique, Prevalence, and intensity of urinary schistosomiasis by country’s subarea

| Ref | Country           | Subarea          | Eggs concentration technique | Sample size | Prevalence (%) | Mean Intensity | Age group (Years) |
|-----|-------------------|------------------|------------------------------|-------------|----------------|----------------|------------------|
| [45] | Nigeria           | Kwara State      | Centrifugation               | 551         | 35.20          | N.R            | 9—16             |
| [46] | Cameroon          | Northern Province| Sedimentation                | 964         | 36             | N.R            | 9—17             |
| [47] | Nigeria           | Plateau State    | Sedimentation                | 242         | 2.07           | 27.8**         | 5—14             |
| [48] | Nigeria           | Kano State       | Centrifugation               | 493         | 44.20          | 107.30**       | 5—16             |
| [49] | Kenya             | Migori County    | Filtration                   | 1768        | 8.90           | N.R            | 7—14             |
| [50] | Nigeria           | Adamawa State    | Centrifugation               | 232         | 47.80          | 8.30**         | 4—15             |
| [51] | Kenya             | Coast Province   | Filtration                   | 12,541      | 41.50          | 45*            | 5—19             |
| [52] | Kenya             | Coast Province   | Sedimentation                | 7093        | 66             | 20**           | 5—21             |
| [53] | Senegal           | Fatick Region    | Filtration                   | 329         | 73.20          | 356.1*         | 5—15             |
| [54] | Nigeria           | Katsina State    | Centrifugation               | 611         | 21.11          | 26.98**        | 10—15            |
| [55] | Kenya             | North Coast      | Filtration                   | 262         | 94             | N.R            | 5—12             |
| [56] | Nigeria           | Ogun State       | Centrifugation               | 487         | 57.1           | 45**           | 6—14             |
| [57] | Malawi            | Chikhwa wa district | Centrifugation | 1642      | 14.20          | N.R            | N.R              |
| [58] | Niger             | Tillabery /Tahoua | Filtration                   | 1642        | 75.40          | 15.50*         | 7,8 & 11         |
| [59] | Kenya             | Coast Province   | Filtration                   | 4031        | 35             | N.R            | N.R              |
| [60] | Ghana             | Brong Afafo Region | Centrifugation | 100        | 50             | N.R            | 6—15             |
| [61] | Senegal           | Fatick Region    | Filtration                   | 682         | 57.6           | N.R            | 5—15             |
| [62] | Cameroon          | Magba Region     | Filtration                   | 382         | 41.10          | 154.7***       | 7—14             |
| [63] | Senegal           | Fatick Region    | Filtration                   | 210         | 57.6           | 185*           | 7—15             |
| [64] | Nigeria           | Lagos State      | Sedimentation                | 102         | 78.43          | N.R            | 5—15             |
| [65] | Burkina Faso      | Ouagadougou      | Filtration                   | 3514        | 8.76           | 6**            | 7—11             |
| [66] | Zimbabwe          | Chikwa Wa Communal Land | Centrifugation | 551     | 60             | N.R            | 9—16             |
| [67] | Nigeria           | Katsina State    | Centrifugation               | 436         | 27.98          | 35.29**        | 12—17            |
| [68] | Zambia            | Lusaka Province  | Filtration                   | 2040        | 9.60           | 31.40**        | 6—15             |
| [69] | Nigeria           | Ogun State       | Centrifugation               | 187         | 64.7           | 0.95*          | 5—15             |
| [70] | Kenya             | Coast Province   | Sedimentation                | 114         | 22.8           | N.R            | N.R              |
| [71] | Angola            | Cubal District   | N.R                          | 785         | 61.80          | N.R            | 9—10             |
| [72] | Yemen             | Taiz, Ibb, Dharmar, Sana’a and Hodiedah Provinces | Filtration | 400     | 23.80          | N.R            | †                 |
| [73] | Nigeria           | Kaduna State     | Centrifugation               | 505         | 12.30          | 2.69**         | 4—15             |
| [74] | Nigeria           | Rivers State     | Sedimentation                | 130         | 23.10          | N.R            | 5—16             |
| [75] | Ethiopia          | Gambella Regional State | Filtration | 304     | 35.90          | 8.76**         | 7—14             |
| [76] | Ethiopia          |Almost all regions | Filtration | 99,726 | 0.20           | N.R            | 10—15            |
| [77] | Nigeria           | Adamawa State    | Centrifugation               | 346         | 32.40          | N.R            | 5—15             |
| [78] | Nigeria           | Taraba State     | Filtration                   | 1153        | 53.08          | N.R            | 6—15             |
| [79] | Nigeria           | Cross River State | Filtration | 200     | 21             | N.R            | 5—15             |

TOTAL 144,755

*Geometric Mean Intensity; N. R, Not reported; **Arithmetic Mean Intensity; † Not clearly defined
researchers as key factors in the transmission of the disease.

In addition, parental factors such as educational and occupational status have been reported by researchers from various endemic settings of US.

Finally, economic and ecological factors like lack of sewage disposal facilities and climate change were reported as determinant factors of the disease.

Pathology and morbidity markers of urinary schistosomiasis

Table 4 presents the pathological consequences and morbidity markers of US by infection phases as reported by the research articles included in this review.

Morbidity markers identified include swimmer’s itch, eosinophilia, terminal haematuria, proteinuria, and dysuria. On a broad note, the morbidities/pathological consequences reported obviously revolve around the urogenital system as shown in Table 4 below. They are majorly associated with the chronic phase of the disease.

Table 5 presents a list of drugs of intervention for US. It shows PZQ as having the highest cure rate and Niridazole as the least.

Generally, the global population treated for schistosomiasis increased from 2008 to 2016 with the exception of 2011 and 2013 when a decline was experienced (Fig. 2). The same applied to the number of SAC treated as well as their treatment coverage within the same period. The highest distribution coverage for PZQ was achieved in 2016 (see Fig. 3). However, the SAC requiring chemotherapeutic intervention with PZQ kept increasing till 2014 (see Table 6 and Fig. 2).

Discussion

Results summary

In summary, the overall findings in this review showed that: (1) of all WHO Regions, Africa is the most endemic zone for US, with Kenya and Senegal recording the highest prevalence and mean intensity respectively; (2) SAC within the range of 5–16 years contribute most significantly to the transmission cycle of the disease globally; (3) gender is a factor to watch out for, with male often recording the highest prevalence and intensity of infection; (4) contact with open, potentially infested water sources contribute significantly to its transmission; (5) parental factors (occupation and educational and occupational status) are major factors.

Table 3 Risk factors of urinary schistosomiasis peculiar to school children

| Risk factor                          | Category                              | References |
|--------------------------------------|---------------------------------------|------------|
| Age                                  | 7—9                                   | [62]       |
|                                      | 5—10                                  | [79]       |
|                                      | 10—12                                 | [55]       |
|                                      | 12—14                                 | [56]       |
|                                      | 11—15                                 | [53]       |
|                                      | 5—15                                  | [69]       |
|                                      | 6—15                                  | [78]       |
|                                      | 13—16                                 | [74]       |
| Gender                               | Male                                  | [49, 53, 54, 62, 63, 65, 67, 75, 78—80] |
|                                      | Female                                | [64, 73, 74] |
| Recreational activities              | Swimming/play in shallow water         | [54, 73]   |
| Water sourcing for domestic use      | *Unwholesome water sources             | [54, 62, 67, 72, 73, 81] |
| Parental occupation/Farm-related activities | Farming                         | [54, 57, 73, 75] |
|                                      | Fishing                                | [54, 57, 62, 67, 73] |
|                                      | Brown collar jobs                      | [54, 67]   |
|                                      | House wives                           | [54]       |
|                                      | Irrigation                            | [20]       |
| Parental educational status          | Illiteracy                            | [72, 73]   |
| Proximity of residence to infested water |                                    | [71, 72, 81] |
| Altitude                             | Valley                                | [68]       |
| Lack of sewage disposal facilities   | Toilet                                | [72]       |
| Changing global climate             |                                       | [20]       |

*Rivers, streams, ponds, and dams

Table 4 Reported morbidities by infection phases of urinary schistosomiasis

| Infection Phase          | Morbidity/Pathological Consequences | References |
|--------------------------|------------------------------------|------------|
| Larval Invasion          | Swimmers itch                      | [54]       |
| Acute (Maturation)       | Eosinophilia                        | [55]       |
| Chronic (Establishment)  | Terminal haematuria                 | [46, 52, 54–56, 58, 62] |
|                          | Proteinuria                         | [52, 56, 66] |
|                          | Dysuria                             | [46, 54, 62, 66] |
|                          | Pseudopapillae                      | [55, 66]   |
|                          | Bladder papillomas/lesion           | [52, 58]   |
|                          | Bladder wall calcification          | [20]       |
|                          | Ureteric fibrosis                   | [52]       |
|                          | Kidney pyelon dilatation            | [55, 58, 66] |
|                          | Ureter dilatation                   | [16, 55, 58] |
|                          | Intravesical mass formation         | [16]       |
|                          | Hydronephrosis                      | [52, 66]   |
|                          | Genital discharge/itching/burning sensation | [69, 82] |
|                          | Genital lesions                     | [16]       |
|                          | Genital swelling/fump               | [69]       |
(5) Education status) predispose SAC to US; (6) economic vis a vis ecological factors play a key role in infection transmission; and (7) in the last decade, a treatment coverage of 45% was never achieved globally for SAC or non-SAC treatment category for US.

The need to treat school-age children (SAC)

Meanwhile, schistosomiasis, an infectious disease of poverty, is easily contracted through poor hygiene and play habits of school children. In majority of areas endemic for US, a peak of morbidity is usually observed in school children within age range 7–14 years [16]. On the long run, it prolongs squalor and as a result, blocks cognitive academic performance and normal growth of children. This culminates in suffering and sometimes, death [17]. The extent of morbidity due to US is strongly linked with the intensity and the length of infection period. Because US is more prevalent in SAC, control programme is directed at them so that the duration of heavy infection intensity could be reduced markedly [18, 19].

Unfortunately, as our findings revealed, majority of SAC are from Africa which had previously been reported to have accounted for an estimate of over 85% of all cases of schistosomiasis globally [20]. Therefore, promoting the health of SAC has been an integral part of the programme of WHO, United Nations Educational, Scientific and Cultural Organization (UNESCO), United Nations Children’s Fund (UNICEF), and other international agencies since the 1950s [21]. SAC are a target group for Mass Drug Administration (MDA) since WHO expert committee on schistosomiasis met for the first time 64 years ago [18, 22].

This is ascertained by the projected budget of about USD 116 million for 2009 to 2013 global procurement and delivery of drug to endemic countries by WHO and the UN systems without custom fees and clearance charges due to existing agreements [23, 24]. In Central Nigeria, study on the epidemiology of US in SAC using the WHO paradigm of ≥50% prevalence has been used as a benchmark for the treatment of the disease in adults [25].

Management strategies of urinary schistosomiasis in SAC and associated challenges

Various strategies have been applied in the control of US. These include indiscriminate mass treatment, active case finding and treatment of particular risk groups such as school-aged children [26]. However, before the advent of PZQ, other drugs effective against different species and stages of development were used (see Table 5). Drugs of intervention for schistosomiasis progressed from antimonial compounds to PZQ which is the drug of choice today [27].

![Fig. 2](image)
mesylate are effective for the treatment of US. Lucanthone hydrochloride was used from 1948 to mid-sixties. When given a short treatment from 3 to 6 days, it had moderate activity against *S. haematobium*. Nitazoxanide is used against *S. mansoni*, *S. japonicum* and *S. haematobium* [28]. Corticosteroids and anticonvulsants are used to treat katayama fever in order to suppress the hypersensitivity reaction and with PZQ to eliminate the already mature adult. PZQ should be administered with great caution in the case of concurrent neurocysticercosis [29]. The use of Artemisinin derivatives as prophylaxis for acute schistosomiasis, possibly in combination with PZQ, has been investigated. However, Artemisinin use in malaria-endemic areas is not encouraged because of anticipated drug resistance [30].

However, the most rapid and cost-effective way to control morbidity due to schistosomiasis is through a chemotherapeutic intervention with PZQ [31]. PZQ and Albendazole can, however, be administered together safely where there is co-endemicity of schistosomiasis and Soil-Transmitted Helminthiasis (STH) [32]. It is already well known that after chemotherapy, cessation of symptoms is evidenced in the reduction of egg excretion, proteinuria, haematuria, urinary iron loss, leucocyturia, and few remaining schistosomes which cannot multiply [17, 18, 33–36]. Consequently, they pose little or no threat to their hosts. Therefore, control programmes should focus on the achievement of a sharp decline in the intensity of infection [17]. Based on this premise, in 2001, the World Health Assembly adopted resolution 54.19 which set a target for all endemic countries to regularly treat over 75% of all SAC at risk of morbidity due to schistosomiasis and STH by 2010 [37, 38].

It is pertinent to state that the result of this review clearly showed that this aim was not achieved (see Table 6).

**Table 6** Proportion of school-age children requiring treatment and the number treated for schistosomiasis in the past decade

| Period of intervention (Year) | Global population treated (Millions) | SAC requiring treatment (Millions) | Reported SAC treated (Millions) | Coverage (%) | References |
|-----------------------------|-------------------------------------|----------------------------------|--------------------------------|--------------|------------|
| 2008                        | 17.5                                | NR                               | 9.6                            | NR           | [87]       |
| 2009                        | 19.6                                | NR                               | 10.8                           | NR           | [88]       |
| 2010                        | 33.5                                | 108.9                            | 21.7                           | 19.9         | [89]       |
| 2011                        | 28.1                                | 111.5                            | 16.5                           | 14.8         | [90]       |
| 2012                        | 42.1                                | 114.7                            | 29.7                           | 25.9         | [91]       |
| 2013                        | 39.5                                | 121.2                            | 26.8                           | 22.1         | [92]       |
| 2014                        | 61.6                                | 123.3                            | 49.2                           | 34.6         | [92]       |
| 2015                        | 66.5                                | 118.5                            | 53.2                           | 42.2         | [32]       |
| 2016                        | 89.2                                | 111.2                            | 70.9                           | 53.7         | [93]       |
| 2017                        | **                                  | **                               | **                            | **           | NA         |

**Data not available yet; SAC School-age Children, NR Not reported, NA Not applicable**

**Fig. 3** A clustered column chart showing the distribution coverage of Praziquantel in the last decade.
Nevertheless, the greatest challenge of MDA is to extend regular drug coverage to reach all the children at risk of morbidity due to infection by helminths [23]. There are two perspectives to this. One, each School-age Child (SAC) treated may not have access to enough PZQ that would clear all the parasites. Two, the distribution coverage may not cater for the whole population of infected SAC. Consequently, symptoms of chronic infection may show up after 5–15 years in children who were partially treated as a result of poor coverage of PZQ [20]. However, the report of a School-Based Treatment carried out in Zanzibar Island, Tanzania, where 8000 pupils were treated showed amazing coverage of 85.2 and 86.9% in Pemba and Unguja Districts respectively [39].

PZQ is not without its adverse reactions like abdominal pain, dizziness, headache, vomiting, diarrhea, round, swollen and itching skin rashes, and fever [40]. These are usually mild and last for 24 h. These are reactions from dying worms.

In addition, studies have shown that false negative results cause infected SAC to escape treatment, leading to chronic condition and if such case occurs after MDA, cure rate may be overestimated and this may be a prelude to drug resistance and further transmission of US [41].

It is hoped that in the nearest future, global schistosomiasis control programmes will receive a boost when the current “evolutionary” process of vaccine-linked chemotherapy culminates in approval by WHO. A good number of these vaccines undergoing preclinical and clinical trials on the field are particularly made for children [42].

Limitations of the review
This review took articles reported in English into consideration instead of including those reported in other languages. Besides, we noticed that mean intensity of infection with US was either underreported or not reported by some authors of articles included in this review article. Consequently, the report of the mean intensity reported here may not be an accurate reflection of what is obtainable among SAC globally.

Conclusion
The prevalence rates and intensities of US vis a vis its impact on SAC, keep increasing from year to year, leading to increase in the global population requiring chemotherapeutic intervention with PZQ. In view of the WHO strategic ambitious plan to eliminate schistosomiasis by 2020 [43] and the findings from this review stipulating that in the last decade, a PZQ distribution coverage of 45% has never been achieved for SAC, it is obvious that this goal, in the face of realities, might not be achieved just like the strategic plan for 2010. Our view is in agreement with the report that if WHO sustains the current treatment trend, elimination is achievable in 2030 [44]. It is imperative that annual control programmes be scaled up marginally, particularly in the African region of the WHO. While US-based researches should be sponsored at the grass-root level to unveil hidden endemic foci, adequate facilities for Water, Sanitation, and Hygiene (WASH) should be put in place in all schools globally.

Acknowledgements
We express our profound gratitude to the authors of the research papers, review articles and online materials used in the course of preparing the manuscript of this review article. Without their meritorious contribution to knowledge about schistosomiasis, this paper would have been written with scanty references.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Authors’ contributions
TEA conceived the review. TEA and TOA searched for relevant literatures and wrote the manuscript. Both authors read and approved the final version of the manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Biological Sciences, Federal University, Dutsin-Ma, Km 65, P.M.B. 5001, Dutsin-Ma, Katsina State, Nigeria. 2Department of Biological Sciences and Biotechnology, College of Pure and Applied Sciences, Caleb University, Imota, Lagos State, Nigeria.

Received: 8 January 2018 Accepted: 21 December 2018

Published online: 18 January 2019

References
1. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014;383(9936):2253–64.
2. World Health Organization. Schistosomiasis. Fact sheet 115 updated January 2017. Available at: http://www.who.int/mediacentre/factsheets/fs115/en/. Accessed on 8 June 2017.
3. Steinman P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis and estimates of people at risk. Lancet Infect Dis. 2006;6(11):641–25.
4. Atalabi TE, Lawal U, Ipinlaiye SI. Prevalence and intensity of genital-urinary schistosomiasis and associated risk factors among junior high school students in two local government areas around Zobe Dam in Katsina state, Nigeria. Parasit Vectors 2016a; 9:388.
5. Atalabi TE, Lawal U, Akinluyi FO. Urogenital schistosomiasis and associated determinant factors among senior high school students in the Dutsin-ma and Safana local government areas of Katsina state, Nigeria. Infect Dis Poverty 2018b; 7:56.


distribution and co-infection with urogenital and intestinal schistosomiasis among primary school children in Migori County, Kenya. East Afr. Med. J. 2016;93(10):522–31.

50. Birmah JS, Gershon J, Shadrach PA, Nganjua J, Yakoh AB, Vandi P, Laurat TJ. Urinary schistosomiasis in communities around Kiti Lake, Shelleng local government area, Adamawa state, Nigeria. Afr. J. Environ. Manag. 2017; 21(1):128–34.

51. Magnussen P, Muchiri E, Mungai P, Ndovu M, Ouma J, Toshia S. A school-based approach to the control of urinary schistosomiasis and intestinal helmint infections in children in Matuga, Kenya: impact of a two-year chemotherapy programme on prevalence and intensity of infections. Tropical Med Int. Health. 1997;2(9):825–31.

52. King CH, Muchiri EM, Ouma JH. Evidence against rapid emergence of Praziquantel resistance among urinary schistosomiasis and reinfection in Senegalese school children where there is a single well defined transmission period. Parasite Vectors. 2015;8:962.

53. Atalabi TE, Adubi TO, Lawal U. Rapid mapping of urinary schistosomiasis: an appraisal of the diagnostic efficacy of some questionnaire-based indices among high school students in Katsina state, Northwestern Nigeria. PLoS Negl Trop Dis. 2017;11(4):e0005518.

54. Njauakhe KH, Vennervald BJ, Madsen H, Mukoko DA, Kimani G, Jasko WG, Benson B. Schistosoma haematobium and soil-transmitted helminths in Tana Delta district of Kenya: infection and morbidity patterns in primary school children from two isolated villages. BMC Infect. 2016;16:57.

55. Morenikeji O, Quazim J, Omoregie C, Hassan A, Nwuba R, Anumudu C, Oluwasogo OA, Fagbemi OB. Prevalence and risk factors of urinary schistosomiasis and associated factors among senior high school students in the Dutse-ma and Safana local government areas of Katsina state, Nigeria. Infect Dis Poverty 2016b; 5:69.

56. Simonoga C, Kazembe LN. Using the hierarchical ordinal regression model to analyse the intensity of urinary schistosomiasis infection in school children in Lusaka Province, Zambia. Infect. Dis Poverty. 2017;6:43.

57. Pozio UF, Odeyemi OM, Sam-Wobo SO, Ounukwor OB, Mogaji HO, Oluwole AS, Abdussalam HO, Stothard JR. Female genital schistosomiasis (FGS) in Ogun state, Nigeria: a pilot survey on genital symptoms and clinical findings. Parasitol. Open. 2017;3(10):1–9.

58. Vinkeles Melchers NVS, van Dam GJ, Shaproski D, Kahama Al, Bienen ET, Vennervald BJ, van Lieshout L. Diagnostic performance of Schistosoma Real-time PCR in urine samples from Kenyan children infected with Schistosoma haematobium: day-to-day variation and follow-up after Praziquantel treatment. PLoS Negl Trop Dis. 2014;8(4):e2807. https://doi.org/10.1371/journal.pntd.0002807.

59. Bocanegra C, Gallego S, Mendizorza JJ, Moreno M, Sulleiro E, Salvador F, Siklatea N, Nindia A, Tchipita D, Joromba M, Kavaya S, Montalva AS, López T, Molina I. Epidemiology of schistosomiasis and usefulness of indirect diagnostic tests in school-age children in Cubal, Central Angola. PLoS Negl Trop Dis. 2015;9(10):e0004555.

60. Sady H, Al-Mekhlafi HM, Mahdy MAK, Lim YAL, Mahmud R, Surin J. Prevalence and associated factors of schistosomiasis among children in Yemen: implications for an effective control Programme. PLoS Negl Trop Dis. 2013;7(8):e2377.

61. Bishop HG, Inabo HI, Efia EA. Prevalence and intensity of urinary schistosomiasis and their effects on packed cell volume of pupils in Jaba LGA, Nigeria. Edorium J Microbiol. 2016;2:13–26.

62. Goodhead DA, Dirisu CG. Prevalence of urinary schistosomiasis among pupils in endemic communities of Rivers state, Nigeria. Am J Microbiol Biotechnol. 2016;3(2):7–12.

63. Geleta S, Alemu A, Getse T, Mekonnen C, Erko B. Prevalence of urinary schistosomiasis and associated risk factors among Abobo primary school children in Gambella regional state, southwestern Ethiopia: a cross-sectional study. Parasite Vectors. 2015;8:215.

64. Grimes JET, Tadesse G, Mekete K, Wuletaw Y, Gebrektadis A, French MD, Harrison WE, Drake LJ, Gardiner IA, Yard E, Templeton MR. School water, sanitation, and hygiene, soil-transmitted helminths, and Schistosomes: national Mappingin Ethiopia. PLoS Negl Trop Dis. 2016;10(3):e0004515. https://doi.org/10.1371/journal.pntd.0004515.

65. Balla HJ, Jabbo AA. Survey of urinary schistosomiasis among school-aged children in the rural communities of Mayo-belwa local government area, Adamawa state, Nigeria. J Nat Sci Res. 2013;3(3):73–7.

66. Houmsou RS, Agere H, Wama BE, Bingbeng JB, Amuta EU, Kela SL. Urinary schistosomiasis and associated risk factors among primary school children in Adim community, Nigeria. Int J Sci. 2017;6:10.

67. Frigerio S, Bert F, Clari M, Fine GD, Riva S, Bergese I, Diouf SG, Alvaro R. Single dose Metrifonate in the treatment of urinary schistosomiasis in northern Senegal. Annals of Global Health. 2016;82(5):841–7.

68. Adenowo AF, Dyijofoye BE, Ogunyinka B, Kappo AP. Impact of human schistosomiasis in sub-Saharan Africa. Braz J Infect. Dis. 2015;19(2):196–205.

69. World Health Organization. Female Genital Schistosomiasis: A Pocket Atlas for Clinical Health-Care Professionals. World Health Organization (WHO/HTM/WNDT/2015/4). 49pp.

70. Farid Z, Bassily S, Kent DC, Hassan A, Abdel-Wahab MF, Wissa J. Urinary CATschistosomiasis treated with sodium ammonium tartrate—a quantitative evaluation. Br. Med. J. 1968b;5365(203):713–4.

71. Ejima IAA. Comparative evaluation of the efficacy of Praziquantel (PZQ) and Nitazoxamide (NTZ) in the treatment of urinary schistosomiasis among school children examined in Idaho and Ibadan local government areas (LGAs) of Kogi state, Nigeria. Int J Mol Med Adv. Sci. 2015;3(1):11–8.

72. Tsvana SA, Mason PR. Single dose Mebendazole in the treatment of urinary schistosomiasis in an area of low prevalence and intensity of infection. Central Afr J Med. 1986;32(6):133–7.

73. Magasia K, Taylor M, Kjetland EF, Naidoo PJ. A review of the control of schistosomiasis in South Africa. Afr. J. Sci. 2015;111(11/12):1–6.

74. World Health Organization. Schistosomiasis: number of people treated, 2008. Ixew Epidemiol. Rec. 2010a; 85 (18): 157–164.
88. World Health Organization. Schistosomiasis: number of people treated, 2009. Wkly Epidemiol. Rec. 2011; 86 (9): 73–80.
89. World Health Organization. Schistosomiasis: population requiring preventive chemotherapy and number of people treated in 2010. Wkly Epidemiol. Rec. 2012; 87 (4): 37–44.
90. World Health Organization. Schistosomiasis: number of people treated in 2011. Wkly Epidemiol. Rec. 2013a; 88 (8): 81–88.
91. World Health Organization. Schistosomiasis: number of people receiving preventive chemotherapy in 2012. Wkly Epidemiol. Rec. 2014; 89 (2): 21–28.
92. World Health Organization. Schistosomiasis: number of people treated worldwide in 2014. Wkly Epidemiol. Rec. 2016a; 91 (5): 53–60.
93. World Health Organization. Schistosomiasis and soil-transmitted helminthiases: number of people treated in 2016. Wkly Epidemiol. Rec. 2017; 49(92): 749–760.